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Abstract 
CD40 signaling is critical for innate and adaptive immunity against pathogens, and the 
cytoplasmic domain of CD40 is highly conserved both within and between species.  A 
novel missense SNP in the cytoplasmic domain of CD40 at position 227 (P227A) was 
identified, which resides on a conserved ancestral haplotype highly enriched in 
individuals of Mexican and South American descent.  Functional studies indicated that 
signaling via human (h)CD40-P227A stably expressed in several B cell lines led to 
increased phosphorylation of c-Jun, increased secretion of the pro-inflammatory 
cytokines IL-6 and TNF-α, and increased Ig production, compared to Wt hCD40.  
Cooperation between hCD40-P227A signaling and BCR- or TLR9-mediated signaling 
was also enhanced, resulting in elevated and synergistic production of IL-6 and Ig.  We 
have thus identified a novel genetic variant of hCD40 with a gain-of-function immune 
phenotype.   
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Introduction 
  CD40 is a member of the TNF receptor (TNFR) family of genes
1 and is expressed 
on B cells and antigen-presenting myeloid cells.  Interactions between CD40 and its 
ligand, CD154, are required for T-dependent B cell responses, including efficient 
germinal center formation, class switching and memory B cell generation
2.  In dendritic 
cells, CD40 ligation leads to enhanced survival and tumoricidal activity, and increased 
production of cytokines and nitrous oxide
3.  Genetic mutations in CD154 cause human X-
linked immunodeficiency with hyper-IgM, type 1 (HIGM1), a disease associated with 
severe immune deficiency and increased susceptibility to bacterial and opportunistic 
infections
4.  Complete deficiencies of CD40 (HIGM3) are also described, and show a 
similar phenotype to HIGM1
5.   
  CD40 is located on chromosome 20q13.1.  Genetic linkage with this region has 
been reported for autoimmune diseases including SLE
6, Juvenile Rheumatoid Arthritis
7 
and Graves’ Disease (GD)
8, making CD40 an attractive candidate contributor to these 
conditions.  Initial reports demonstrated genetic linkage of GD with a region of 
chromosome 20q11.2-13.1 that contains the CD40 locus
8.  Further evaluation revealed 
the C allele or CC genotype of a Kozak sequence polymorphism in the 5'-UTR at position 
-1 of CD40 to be associated with GD in Caucasian cohorts from the U.S.
9, Korea
10 and 
Japan
11.  However, two large GD cohorts from the UK failed to demonstrate this 
association
12,13.  Functional evaluations in immune cells from CC genotype subjects show 
higher surface CD40 and enhanced CD40 signaling.  Enhanced translational efficiency 
from DNA strands with the rs1883832 C allele has been proposed as underlying elevated 
CD40 protein expression.  
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  Chadha et al. used a family-based haplotype tagging approach in a cohort of 408 
European-Caucasian SLE families from the UK to test the hypothesis of association 
between CD40 and SLE incidence
14.  The results of this study failed to provide 
convincing evidence of association with the occurrence of SLE and single SNPs or SNP 
CD40 haplotypes.  However, the possibility that CD40 contributes to particular disease 
symptoms or severity was not explored, in either this or the GD studies. 
  Our group recently published a fine-mapping study of the chromosome 20q13.1 
region
6.  This study, while not specifically designed to target the CD40 locus, identified 
modest evidence of association with SNPs in and around the CD40 locus in a cohort of 
230 SLE families.  Interestingly, the evidence for association in the region of CD40 
weakened when only Caucasian families were considered, suggesting that a portion of the 
effect was attributable to non-Caucasian pedigrees, which comprised only 20% of the 
total sample. 
  Here, we describe genetic and functional characterization of a novel missense 
SNP in exon nine of the CD40 gene resulting in a proline to alanine amino acid 
substitution at position 227 of CD40.  Our data demonstrate an unusual population 
enrichment of this variant on an ancestral haplotype present in Mexican and South 
American populations.  Functional analyses using well-characterized mouse and human 
B cell lines reveal that hCD40-P227A signals resulted in enhanced ability to activate B 
cell function, amplified cooperation with the B cell receptor (BCR) and Toll-like receptor 
9 (TLR9), and increased activation of a subset of early signaling pathways.  This "gain-
of-function" suggests a possible role for the P227A polymorphism in increasing efficacy 
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of immune responses to pathogens endemic to Mexico and South America.  This may 
also predispose individuals to a general susceptibility to lymphoid hyperreactivity. 
For personal use only. on November 7, 2014.  by guest    www.bloodjournal.org From   6
Materials and Methods 
Human DNA samples and SNP genotyping.   
  The Human Genome Diversity Panel was used to characterize the worldwide 
prevalence of P227A.  This DNA collection, comprised of 1064 individuals represents 52 
world populations
15.  HGDP samples were genotyped for rs11086998 using the 
Sequenom MassARRAY according to manufacturer-recommended protocols. 
Cells 
  The human B cell line T5-1
16 and the mature mouse B cell lines CH12.LX
17 and 
M12.4.1
18 have been described previously; both were chosen as responsive to signals 
from both CD40 and TLRs.  Cells were maintained in RPMI 1640 with 10% heat-
inactivated FCS (Atlanta Biologicals, Norcross, GA), 10µM 2-ME (GIBCO, Grand 
Island, NY), penicillin and streptomycin (B cell medium, BCM).  Stable transfectants 
expressing WT hCD40 or a chimeric molecule consisting of  the hCD40 extracellular and 
transmembrane domains and the LMP1 intracellular domain (hCD40-LMP1) have been 
described and were maintained in 400 µg/ml G418 disulfate (Research Products 
International)
19.  In all experiments, >3 individual stably transfected subclones with 
similar levels of endogenous and transfected hCD40 or mouse (m)CD40 were tested, and 
signaling via each transfected molecule was compared to signaling via the clone’s 
endogenous CD40, to ensure that results obtained were not attributable to clonal 
variation.  Hi5 insect cells infected with WT or hCD154-expressing baculoviruses have 
been described
20.  Hi5 cells grow at 25°C and lyse at 37°C, providing a source of 
membrane-bound trimeric hCD154 without overgrowing cultures.  While agonistic α-
CD40 mAbs recapitulate most CD40 effects on B cells, including recruitment of TNF 
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receptor-associated factor (TRAF) 2 and TRAF3, activation of MAPK/SAPK and NF-
κB, and secretion of TNF-α and Ig, membrane-bound CD154 is required for optimal 
TRAF6 recruitment and IL-6 production
21.  Although Hi5 cells expressing baculovirus-
encoded mCD154 cells are available, mCD154 not only optimally activates mCD40, but 
can also occasionally modestly activate hCD40.  However, hCD154 doesn’t stimulate 
mCD40, so results obtained with hCD154 are not attributable to stimulation of mCD40
21.  
Therefore, species-specific agonistic Abs were used to evaluate the effectiveness of the 
internal control, mCD40.  
Stable transfection of B cell lines 
  hCD40-P227A cDNA was subcloned into the plasmid pRSV5.neo* for stable 
expression in CH12.LX and M12.4.1 cells, which were transfected by electroporation
18.  
Chimeric molecules consisting of the extracellular and TM domain of mCD40 and 
intracellular portions of either hCD40 or hCD40-P227A were constructed by overlap-
extension PCR to generate mCD40-hCD40 and mCD40-hP227A
22.  These cDNAs were 
subcloned into pRSV5.neo* for expression in T5-1 human B cells by electroporation at 
250V, 30ms with a BTX Electro Square Porator ECM 830 (BTX Harvard Apparatus; 
Holliston, MA).  Stable clones were maintained in 400 µg/ml G418 (for CH12.LX and 
M12.4.1; Sigma, St. Louis, MO), or 1200 µg/ml G418 for T5-1 clones.  Surface 
expression of endogenous and transfected CD40 was determined by immunofluorescence 
flow cytometry as described for hCD40WT
19.  Clones with similar levels of both 
endogenous and transfected CD40 were used for experiments, with > 2 individual clones 
tested for each B cell function.   
Abs and chemicals 
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  Stimulatory Abs used include:  1C10 (rat anti-mCD40 IgG2a), G28-5 (mouse 
anti-hCD40 IgG1), and the isotype controls mAB72 (rat anti-human α-L-fucosidase 
IgG2a) and MOPC21 (mouse IgG1).  The 1C10 hybridoma was a kind gift of Dr. Frances 
Lund (Trudeau Institute, Saranac Lake, NY).  The G28-5, mAB72, and MOPC21 
hybridomas were purchased from the American Type Culture Collection (Manassas, 
VA).  Hybridoma supernatants were purified by saturated ammonium sulfate 
precipitation and the mAbs quantified by isotype-specific sandwich ELISA.  Goat anti-
mouse µ chain specific F(ab’) 2 was used to engage the BCR (Jackson ImmunoResearch 
Laboratories, West Grove, PA).  
  The following Abs were used for immunoblotting.  Rabbit anti-TRAF1 (N19), 
rabbit anti-TRAF3 (H122), rabbit anti-JNK1/2 (FL), and mouse anti-YY1 (H-10) were 
purchased from Santa Cruz Biotechnology.  Rabbit anti-TRAF2 and chicken anti-TRAF6 
were purchased from Medical and Biological Laboratories (Watertown, MA). Polyclonal 
sheep anti-GST-hCD40 Ab was prepared by Elmira Biologicals (Iowa City, IA) as 
described previously
23.  Rabbit anti-pJNK1/2, rabbit anti-pIκBα, and rabbit anti-IκBα 
were purchased from Cell Signaling Technology.  Rabbit anti-phosphorylated c-Jun 
(Ser63) and HRP-conjugated anti-sheep Ab were purchased from Upstate Biotechnology 
(Charlottesville, VA).  Rabbit anti-phosphorylated c-Jun (Ser73) was purchased from 
Biosource/Invitrogen (Carlsbad, CA).  Mouse anti-actin (C4) was purchased from 
Chemicon (Temecula, CA).  Mouse anti-GAPDH (6C5) was purchased from Abcam 
(Cambridge, MA). HRP-conjugated goat anti-mouse, goat anti-rabbit, and donkey anti-
chicken Ab were purchased from Jackson ImmunoResearch Laboratories. 
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  The Class-B(K) stimulatory CpG oligodeoxynucleotide 2084 5’-
TCCTGACGTTGAAGT-3’ and the non-stimulatory oligodeoxynucleotide 2087 5’-
TCCTGAGCTTGAAGT-3’ have been described previously
24 and were purchased from 
Integrated DNA Technologies (Coralville, IA).  The TLR7/8 agonist R848 was purchased 
from Alexis Biochemicals (San Diego, CA). 
  Sheep erythrocytes for IgM secretion assays were purchased from Elmira 
Biologicals (Iowa City, IA), and guinea pig complement was purchased from Invitrogen 
Life Technologies (Carlsbad, CA).  
IgM and cytokine secretion assays 
  CH12.LX and its subclones produce IgM reactive against phosphatidylcholine, a 
component of erythrocyte cell membranes
25.  Ig-secreting cells were quantified by direct 
plaque-forming cell (Pfc) assay on a lawn of SRBC as described
25.  Quantitative ELISAs 
for IL-6 and TNF-α have been described
25.   
Signaling and TRAF degradation assays 
  The JNK and c-jun phosphorylation
26 and TRAF degradation assays
19 were 
performed as described.  Cells were stimulated at a ratio of 1 Hi5:5 B cells.   
Immunoprecipitation of hCD40 
  TRAF recruitment and co-immunoprecipitation was performed as described by 
lysis in 1% Brij-58
27.  The Brij-soluble fraction corresponds to the non-raft portion of the 
cell lysate, while the Brij-insoluble fraction corresponds to the lipid rafts.  Samples were 
diluted in 2X SDS-PAGE loading buffer, heated to 95°C for 5 min, and analyzed by 
SDS-PAGE. 
Immunoblots 
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  Proteins were resolved on 10% SDS-PAGE and transferred to Immulon-P 
membranes (Millipore).  Membranes were blocked with 10% nonfat dry milk for 1h at 
25°C, incubated with primary Ab overnight at 4°C, washed 3X, and incubated with 
secondary Ab for 1h at 25°C.  Blots were developed with ECL (Pierce Biotechnology, 
Rockford, IL), read on a low-light digital camera (LAS-1000; Fujifilm Medical Systems 
USA, Stamford, CT), and quantified using Image Gauge (Fujifilm). 
Results 
  CD40 signaling is critical for coordination of T-cell dependent B cell responses 
and myeloid cell activation.  Naturally occurring coding sequence variation in the CD40 
gene is rare, with only 2 non-synonymous SNPs recorded in the public domain.  The 
infrequency of coding region variation in the CD40 locus likely indicates the importance 
of the WT sequence in proper function of the immune system.  We therefore 
hypothesized that coding region variation in the CD40 locus at a frequency high enough 
to be catalogued in public databases might lead to properties that confer a selective 
advantage for a given population.  Because of its proximity to CD40 intracellular 
signaling sequences, the rs11086998 variant was evaluated for functional effects.  SNP 
rs11086998 results in a C to G transversion in exon nine, resulting in a proline-to-alanine 
missense substitution at amino acid 227 (P227A) in the cytoplasmic domain of CD40 
(Fig 1A).  This domain is 62aa long and contains three TRAF binding sites that link the 
ligand-aggregated receptor to downstream NF-κB and JNK signaling pathways.  The 
P227A polymorphism is in a proline-rich spacer region located between the membrane-
spanning portion of CD40 and the proximal TRAF6 binding site (Fig. 1A). 
Population Prevalence of rs11086998 
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  To evaluate the worldwide population frequency of rs11086998, we genotyped 
the P227A SNP in the Human Genome Diversity Panel (HGDP), a set of 1064 DNA 
samples representing 52 world populations
15.  The results demonstrated a high prevalence 
of rs11086998 in populations of Mexico and South America (mean allele frequency 29%) 
compared with other populations (Fig. 1B).  The Mexican Pima population demonstrated 
the highest allele frequency (46%) (Fig. 1C).  In sharp contrast, the rs11086998 G allele 
was rare in Central, East Asian and Middle Eastern populations (mean allele frequency ≤ 
1%), and wasn’t present on any of the African, Melanesian or European chromosomes 
tested. 
  To test whether this global pattern of diversity is unusual, we estimated how often 
alleles common in the Americas are present at low frequencies elsewhere in the world, 
using 404 microsatellite markers genotyped in the HGDP DNA samples
28.  Of 486 alleles 
present at a frequency of 20-40% in the Americas, only one showed a frequency of <5% 
in all other HGDP populations (data not shown), suggesting that population stratification 
of the G allele of rs11086998 is rare.  
  Overall CD40 haplotype structure was evaluated by typing 13 haplotype-tagged 
SNPs in selected HGDP populations (Americas, East Asia, Central Asia, Europe).  This 
analysis identified three common haplotypes (Figure 1D, i-iii) that account for ~ 2/3 of 
chromosomes (Americas - 68.9%, E. Asia - 86.6%, C. Asia - 63.0%, Europe - 62.9%).  
The rs11086998 C-to-G substitution is carried on a unique ancestral haplotype that 
contains additional tightly linked SNPs (iv), and shows three recombinant variants (v-vii).  
In this sample, the rs11086998 ancestral haplotype was present at a frequency of 27.5% 
in the Americas, compared with 2.4% in Central Asia and 1.8% in East Asia.  The 
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rs11086998 G allele was not found in European samples, consistent with Chadha et al.
14.  
No lower frequency haplotypes (viii-xiii) in the other three populations were observed in 
samples from the Americas. 
  Because rs11086998 G is a proline to alanine substitution near important 
signaling motifs, we hypothesized that the G allele might lead to altered function of 
CD40.  To examine functional effects of hCD40-P227A on B cell activation, cDNA 
constructs were first stably expressed in mouse B cell lines CH12.LX and M12.4.1, 
which are frequently used models for studying CD40-mediated B cell activation
17,18.  
Previous work has shown that mouse and hCD40 signal indistinguishably in this system, 
as measured by recruitment of TRAF 1, 2, 3, and 6
29; activation of MAPK/SAPK family 
members
29; activation of NF-κB and AP-1 transcription factors
30; induction of pro-
inflammatory cytokines
25; and IgM secretion
18.  A strong advantage of this system is that 
it allows us to use the endogenous mCD40 as an internal control for clone-to-clone 
variation in absolute responses to various signals, because mAbs specific to mouse or 
hCD40 do not cross-react, and hCD154 does not stimulate mCD40 (Refs. cited above). 
This experimental system also allowed us to study the cooperation of CD40 signals with 
other immune receptors, including the BCR and TLR9.   
CD40-mediated IgM secretion in cells expressing hCD40-P227A 
  A critical role of the CD40-CD154 interaction is Ig production by B cells
2, so we 
first tested the effect of hCD40-P227A signaling on Ig secretion.  When compared to 
expression-matched levels of stably expressed hCD40WT or to endogenous mCD40, 
hCD40-P227A signaling resulted in significantly increased Ig secretion (Fig. 2).  This 
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trend was observed whether cells were stimulated with membrane-bound hCD154 (Fig. 
2A) or with agonistic α-CD40 Abs (Fig. 2B).   
  Signaling through latent membrane protein-1 (LMP1), an oncogenic mimic of 
CD40 encoded by the B-lymphotropic Epstein Barr virus (EBV), also results in 
abnormally increased Ig secretion by B cells
22.  Expression of LMP1 in CD40-deficient 
mice restores humoral immunity, but results in B cell hyperactivity and autoreactivity
22, 
as well as exacerbated collagen-induced arthritis
31.  We thus wished to directly compare 
the magnitude of elevated Ig secretion induced by hCD40-P227A to that induced by a 
chimeric molecule consisting of the extracellular and transmembrane portion of hCD40 
and the intracellular domain of LMP1 (hCD40-LMP1) that we have previously exploited 
to study LMP1 signaling
19.  The magnitude of Ig secretion stimulated by hCD40-P227A 
signaling was similar to the elevated levels stimulated by hCD40-LMP1 (Fig. 2C). 
  Previous work shows that simultaneous engagement of the BCR and CD40 leads 
to synergistic production of IgM, IL-6, and TNF-α
25, so we investigated whether BCR-
CD40 cross-talk was enhanced by hCD40-P227A signaling.  Fig. 2D shows both 
endogenous mCD40 and hCD40WT synergized in IgM production when stimulated 
simultaneously with BCR and CD40 agonists.  However, synergistic production of IgM 
was greatly enhanced by hCD40-P227A compared to hCD40WT.       
IL-6 production via hCD40-P227A signaling 
  IL-6 is a pro-inflammatory cytokine induced by CD40 signaling that contributes 
to Ig production and plasma cell differentiation
32.  IL-6 is elevated in autoimmune patient 
sera and contributes directly to disease pathogenesis in autoimmune mouse models
33.  We 
have previously shown that, unlike most CD40 effects on B cells, the production of IL-6 
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requires a source of membrane-bound CD154, and cannot be induced by agonistic Abs
21.  
To test if hCD40-P227A signaling resulted in increased IL-6 production, we stimulated B 
cells with hCD154 expressed by insect cells.  Supernatants were collected at 48h, the 
peak of the response, and analyzed by quantitative ELISA
21.  IL-6 production was 
enhanced upon hCD40-P227A signaling vs. hCD40WT (Fig. 3A).  More IL-6 was 
produced at all time points of stimulation in cells expressing hCD40-P227A, although 
kinetics of IL-6 production were similar in response to hCD40WT (Fig. 3B).   
  As mentioned above, previous work showed that CD40 binding by agonistic α-
CD40 Abs is not sufficient to induce IL-6; rather, a membrane-bound form of CD154 is 
required to elicit IL-6 production
21.  However, B cells expressing hCD40-LMP1 or 
splenocytes isolated from mCD40-LMP1 transgenic mice secrete IL-6 in response to 
agonistic α-CD40 Abs
22.  Like hCD40-LMP1, hCD40-P227A signaling triggered via 
agonistic α-hCD40 Abs, but not α-mCD40 Abs, resulted in detectable levels of IL-6 (Fig. 
3C), indicating that hCD40-P227A required a lower signaling threshold to elicit IL-6 
production.   
  Because hCD40-P227A induced enhanced synergistic IgM, and IL-6 contributes 
to IgM secretion, we tested for enhanced synergistic IL-6 secretion by hCD40-P227A 
signaling.  hCD40-P227A or hCD40WT cells were stimulated for 48h with hCD154 or 
α-CD40 Abs ± goat α-mouse IgM F(ab’)2 (α-BCR).  Enhanced synergistic IL-6 
production was observed in hCD40-P227A-expressing cells stimulated with hCD154 + 
α-BCR (Fig. 3A) and α-hCD40 Ab + α-BCR (Fig. 3C).  Synergistic production of IL-6 
was not observed in cells expressing hCD40WT, even at lower doses of hCD154 (data 
not shown).   
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    CD40 also cooperates with TLR9 to enhance IL-6 production
34 and TLR9 
cooperates with the BCR to increase B cell proliferation and Ig production
24.  TLR9 
recognizes unmethylated CpG motifs present in both self and bacterial DNA and 
contributes to autoimmune disease pathogenesis
35.  To test if hCD40-P227A 
demonstrated enhanced cooperation with TLR9 in IL-6 production, cells were stimulated 
for 20h with hCD154 + stimulatory CpG 2084 or control CpG 2087.  hCD40-P227A 
signaling, when combined with a TLR9 stimulus, resulted in markedly enhanced 
synergistic IL-6 production (Fig. 3D).  hCD40WT also induced synergistic IL-6 
production in combination with a TLR9 agonist, but the effect was only slightly more 
than additive. 
  Previous work showed that hCD40 and mCD40 bind TRAFs similarly, activate 
similar downstream signaling pathways, and lead to the same functional outcomes when 
expressed in either mouse or human B cells.  This is not surprising, as the cytoplasmic 
domains of mouse and hCD40 are highly conserved, as are the TRAF molecules to which 
they bind
29.  Thus, the well-characterized mouse cell lines used here provided an 
appropriate and valid model for the assessment of hCD40-P227A function with 
endogenous mCD40 as an internal control.  However, we wished to confirm that hCD40-
P227A also delivers enhanced signals to human, as well as mouse, B cells.  We stably 
expressed chimeric constructs with the extracellular domain of mCD40 and the 
intracellular domain of either hCD40WT or hCD40-P227A (mCD40-hCD40 and 
mCD40-hP227A, respectively) in the human B cell line, T5-1.  Cells were stimulated for 
48h with mCD154 ± 1 µg/ml R848, a TLR7/8 agonist, and supernatants analyzed by 
quantitative human IL-6 ELISA.  As observed with hCD40-P227A signaling in mouse B 
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cells (Fig. 3D), mCD40-hP227A signaling resulted in enhanced synergistic production of 
IL-6 in cooperation with TLR7/8 stimulation (Fig. 4).  This verifies the use of mouse B 
cell lines as a valid model for hCD40-P227A signaling, similar to the well-established 
comparable WTCD40 signaling in mouse vs. human B cells. 
TNF-α production induced by CD40-P227A signaling   
 TNF-α is secreted by mouse and human B cells upon CD40 signaling and acts in 
an autocrine and paracrine fashion to promote proliferation and Ig secretion
20.  TNF-α 
contributes to CD40-mediated Ig secretion via interaction with B cell-expressed 
CD120b/TNFRII
20.  Although induction of TNF-α following CD40 signaling is 
independent of TRAFs 1, 2, or 3, a direct interaction of TRAF2 with TNFRII is required 
for full Ig secretion in response to CD40
20.  Because hCD40-P227A signaling resulted in 
enhanced IgM secretion, we tested whether TNF-α itself was increased.  Fig. 5 shows 
hCD40-P227A signaling led to earlier increases in TNF-α production (1h) vs. 
hCD40WT, and the increase was more pronounced at 2h and 4h.  Although some reports 
suggest that TNF-α can also enhance IL-6 production by B cells
36, we have not seen this 
dependence in CD40 signaling
37.  Previous work showed that addition of blocking Abs 
against IL-6 and TNF-α to CD40-stimulated cultures decreases Ig secretion more than 
blocking either IL-6 or TNF-α alone, indicating that both these cytokines contribute to 
CD40-mediated Ig secretion
38.  When IL-6 and TNF-α are blocked following hCD40-
P227A or endogenous mCD40 signaling, the increased IgM secretion observed by 
hCD40-P227A decreases to a similar level to endogenous mCD40 (not shown).  Thus, 
both elevated IL-6 and TNF-α contribute to the increased IgM secretion induced by 
hCD40-P227A vs WThCD40. 
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Phosphorylation of JNK and c-Jun  following hCD40-P227A signaling 
  Early events following CD40 signaling include the activation of MAPK/SAPK 
cascades
29.  Compared to CD40, JNK activity is augmented and sustained during LMP1 
signaling, contributing to the enhanced IL-6 production induced by this viral mimic
27.  c-
Jun is a component of the AP-1 transcription factor which, in addition to NF-κB and 
C/EBPβ/γ, contributes to il-6 transcription in B cells following CD40 engagement
30.  
hCD40-P227A signaling increased IL-6 production, so we tested if JNK or its 
downstream target, c-Jun, had altered kinetics or magnitude of phosphorylation following 
CD40 engagement.  JNK phosphorylation downstream of hCD40-P227A signaling was 
modestly increased from that induced by hCD40WT or endogenous mCD40 in 
magnitude, but did not display altered kinetics (Fig. 6A).  More striking was the more 
substantial amount of the JNK target c-Jun that was phosphorylated (Ser 63/73) following 
hCD40-P227A signaling compared to hCD40WT (Fig. 6B, C).  NF-κB, ERK, p38, and 
Akt activity following hCD40-P227A signaling were not reproducibly altered compared 
to hCD40WT (not shown).  
TRAF binding and degradation following hCD40-P227A signaling 
  CD40 mediates intracellular signaling principally via binding to adapter 
molecules TRAF1, TRAF2, TRAF3, and TRAF6, although some TRAF-independent 
signaling events have been reported
39.  Previous work has shown that distinct TRAFs are 
required for specific CD40 signaling events (reviewed in
29).  TRAF6 is required for 
CD40-mediated IL-6 secretion by B cells, which is independent of TRAFs 1, 2, and 3
32.  
Because the P227A mutation is three residues upstream of the TRAF6 binding site and 
signaling through hCD40-P227A enhanced c-Jun phosphorylation and IL-6 production, 
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we tested whether the P227A mutation affected TRAF binding to CD40.  When hCD40 
was immunoprecipitated
27, hCD40-P227A bound TRAF1 (not shown), TRAF2, TRAF3, 
and TRAF6 with similar stoichiometry as hCD40WT (Fig. 7A).  hCD40-P227A-induced 
degradation of TRAF2 and TRAF3 was also similar to hCD40WT (
19 and Fig. 7B).  
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Discussion 
  The present study describes a novel coding region polymorphism in the human 
CD40 gene, rs11086998.  The minor G allele of rs11086998 results in a proline to alanine 
substitution (P227A) in the intracellular, membrane proximal region of CD40, three 
amino acid residues proximal to the TRAF6 binding site.  The G allele of rs11086998 
demonstrated unusual population stratification, with allele frequencies in Mexican and 
South American populations averaging 29% compared to other populations where the G 
allele frequency was < 2%.   
  The unusual global allele frequency distribution of rs11086998 G could reflect 
positive selection after its arrival in the Americas, or demographic history such as a 
population bottleneck/genetic drift when the American continents were populated 15,000 
to 20,000 years ago
40, or in the ensuing expansion phase.  Extended haplotype 
homozygosity (EHH)
41 represents one approach to test for positive selection.  This 
method compares linkage disequilibrium (LD) surrounding an allele of interest to other 
haplotypes at the same locus.  A longer stretch of LD surrounding the allele of interest 
suggests positive selection.  Using EHH, we compared LD structure surrounding 
chromosomes harboring rs11086998 G versus chromosomes with the C allele in HDGP 
Mexican and South American subjects.  A core haplotype of 20 markers around the 
CD40 locus from markers rs6065924 to rs1883833 was defined.  Additional markers 
were genotyped in each direction from the core haplotype (24 markers downstream, 23 
markers upstream, data not shown) and the decay of LD from the core haplotype 
estimated.  We were unable to detect any differences in the length of the LD signal for 
either allele of rs11086998 (data not shown).  The failure to identify EHH for the 
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rs11086998 G allele may reflect limitations of the method, and should not be interpreted 
as indicating that selective pressure was not acting on rs11086998 G in the Americas.  
EHH is most sensitive in detecting positive selection for variants relatively recent in 
population history (<10,000 years old) and when recombination in the region of interest 
is low
41.  Our data suggest that rs11086998 G is ancient, given that the identical 
haplotype is present in Asian chromosomes at low frequency (Figure 1D, haplotype iv 
and vi).  In addition, our data support a relatively high rate of recombination in the CD40 
region (data not shown).  Both factors limit sensitivity of EHH to detect positive 
selection.  Because we could not rule out a role for positive selection of this allele, it is 
interesting to speculate that this allele may have evolved or persisted in these populations 
to provide enhanced defense against pathogens endemic to Mexico and South America, 
including Plasmodium falciparum and Trypanosoma cruzi, the causative agents of 
malaria and Chagas’ disease, respectively.  Recent evidence suggests that treatment of 
mice with CD154 mimetics enhances the immune response to T. cruzi, promoting 
parasite clearance and decreasing mortality
42.  Carriers of the G allele of rs11086998 may 
have a similar enhanced immune response to T. cruzi infection and be less likely to 
develop complications of chronic Chagas’ disease which can involve the cardiac, 
nervous, and digestive systems
42.  Future experiments in an hCD40P227A transgenic 
mouse will test this possibility. 
  The hCD40-P227A mutation conferred a gain-of-function phenotype, as B cells 
expressing hCD40-P227A produced increased amounts of Ig upon CD40 engagement 
(Fig. 2), due in large part to increased production of known contributors to Ig secretion, 
TNF-α and IL-6 (Fig. 3-5).  Importantly, these cytokines also contribute to B lymphocyte 
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and myeloid cell activation in chronic inflammatory diseases
33,43.  TRAF binding by 
hCD40-P227A was not detectably altered compared to hCD40WT (Fig. 7A), consistent 
with the location of this mutation outside all known TRAF binding sites
29.  
Phosphorylation of c-Jun at JNK-specific residues Ser63/73 was consistently enhanced 
(Fig. 6).  c-Jun forms one component of AP-1, a transcription factor required for CD40-
mediated il6 transcription, and thus could contribute to increased IL-6 production upon 
hCD40-P227A signaling
30.  
  CD40 plays important roles in T-dependent immune and autoimmune responses 
including Ig secretion, GC formation, and isotype switching
2.  Consistent with the 
hypothesis that hCD40-P227A is a gain-of-function mutation, Ig secretion in response to 
hCD40-P227A signaling was enhanced, and increased even further when combined with 
a BCR signal (Fig. 2B).  Previous studies have shown that a CD40 signal can rescue 
anergic, autoreactive B cells, reconstituting robust isotype-switched antibody responses
44.  
CD40 can also rescue B cells from CD95/Fas-mediated apoptosis
45. The work presented 
here suggests that hCD40-P227A may have an increased capacity to participate in this 
process.   
  While stimulation with membrane-bound hCD154 is normally required for IL-6 
production, hCD40-P227A signaling in response to agonistic α-hCD40 Abs was 
sufficient to induce IL-6 (Fig. 3A).  This suggests that hCD40-P227A has a lower 
signaling threshold required for IL-6 induction, which contributes to the increased Ig 
production upon hCD40-P227A engagement.  Because blocking IL-6 already 
significantly reduces Ig production by CH12.LX in response to Wt CD40
38 (not shown), 
this approach could not provide clear information on how much the increase in hCD40-
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P227A-mediated Ig production depends on increased IL-6, but it makes an important 
contribution.      
  hCD40-P227A signaling induced enhanced CD40-mediated functions, including 
cytokine and Ig secretion, but did not show enhanced TRAF binding (Fig. 7A) or altered 
degradation of TRAF2 or TRAF3 (Fig. 7B).  This could be due in part to the inability of 
available techniques to detect subtle changes in TRAF binding.  Alternatively, hCD40-
P227A may mediate its effects in a TRAF-independent manner, as TRAF-independent 
CD40 signaling has been reported previously
39.  One candidate for mediating some of 
these events is Janus kinase 3 (Jak3), which is reported to associate with the proline-rich 
spacer region upstream of the TRAF6 binding site corresponding to the site of the 
hCD40-P227A mutation
46.  Jak3 phosphorylation and activation of STAT3 upon CD40 
signaling were reported in Ref. 46 to play a role in CD40-mediated upregulation of 
CD23, ICAM-1, and LT-α in vitro.  However, B cells from Jak3-deficient patients reveal 
no defects in CD40 signaling.  Similarly, CD40
-/- mice reconstituted with a mCD40 
transgene with the proline-rich spacer region deleted (a.a. 222-230) show no defects in 
CD40-mediated isotype switching and B cell activation
47.  It is thus still an open question 
whether Jak3 makes important and nonredundant contributions to CD40 signals; we have 
not been able to detect Jak3 binding to CD40 in B cells (not shown).   Because most 
CD40-associated proteins studied to date were first identified by the yeast two-hybrid 
method, which can miss associations that require mammalian-specific posttranslational 
modifications, newer proteomic approaches may be profitable in identifying additional 
CD40-associated signaling proteins that could be involved in the enhanced signaling by 
hCD40-P227A.        
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  This study focused on hCD40-P227A signaling effects in B cells, but CD40 is 
also expressed on other immune cells including activated T cells, dendritic cells, and 
plasmacytoid dendritic cells (pDCs)
1.  Stimulation of pDCs via CD40 and TLR9 induces 
synergistic production of type I IFN and IL-12p70
35.  Furthermore, pDC-derived type I 
IFN and IL-6 can induce plasma cell differentiation of CD40-activated human B cells
48.  
Future studies will examine whether hCD40-P227A also provides gain-of-function 
signals to myeloid-derived cells.  
  The enhanced functional signaling of hCD40-P227A makes rs11086998 G a 
compelling candidate for association with immunity to pathogens endemic to Mexico and 
South America or with susceptibility to lymphoid hyperreactivity.  We have not 
identified any individuals homozygous for the G allele of rs11086998, suggesting that 
two copies of this gain-of-function allele may be detrimental to the host, possibly due to 
CD40 effects on vascular endothelium, which also expresses CD40.  While association of 
rs11086998 G with SLE incidence was not seen in the Hispanic populations we tested 
(data not shown), there is a documented tendency to increased SLE severity, particularly 
lupus nephritis, in patients with Hispanic ethnicity
49.  It is therefore possible that the 
hCD40-P227A polymorphism can exacerbate SLE in patients who have already 
developed the disease, which the available data cannot reveal.  It is currently not feasible 
to gain access to sufficient clinical samples from patients who have this CD40 
polymorphism, for meaningful experiments on fresh human samples.  However, the 
abundant published documentation that mCD40 and hCD40 signal using the same 
mechanisms, and with the same outcomes, in normal B cells, assures that the findings 
reported here are highly relevant to function of hCD40-P227A in human B cells.  A 
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transgenic mouse expressing a mouse CD40 molecule with this interesting gain-of-
function polymorphism is currently being produced to study effects on in vivo immunity 
to pathogens, as well as susceptibility to exacerbated disease in autoimmune models.   
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Figure Legends 
Figure 1:  The G allele of rs11086998 changes the amino acid sequence of CD40 at 
position 227 from proline to alanine and is enriched in individuals from Mexico and 
South America.  A.  Amino acid sequence of the CD40 intracellular domain.  The 
position of proline 227 (red asterisk) and the location of the downstream TRAF binding 
sites are noted (blue boxes).  B.  SNP rs11086998 was genotyped in the Human Genome 
Diversity Panel (HGDP) representing seven geographic regions worldwide .  Samples 
typed were individuals from equatorial Africa (N=150), Central Asia (N=67), the Middle 
East (N=345), East Asia (N=226), Melanesia (N=39), Europe (N=119) and Mexico and 
South America (N=108).  C.  Results from the Central and South American samples: 
Pima (N=25), Mayan (N=24), Columbian (N=13), Karitiana Brazilian (N=24) and Surui 
Brazilian (N=21).  D.  Thirteen markers across CD40 were genotyped in Central and 
South American (N=108), European (N=119), Central Asian (N=43) and East Asian 
(N=59) individuals from the HGDP.  The predicted ancestral haplotype is shown in blue, 
with haplotype-tagging SNPs shown in red; the P227A SNP is shown in yellow, with 
adjacent haplotype-tagging SNPs shown in purple.  Haplotypes were analyzed by 
Haploview 
50. 
Figure 2:  IgM secretion stimulated by hCD40-P227A versus Wt hCD40.   
A.  CH12.LX cells stably expressing hCD40WT (WT) or hCD40-P227A (P227A.1, 
P227A.2) were stimulated for 72 hours with insect cells infected with Wt baculovirus 
(WT-Hi5), mCD154 expressing baculovirus (mCD154), or hCD154 expressing  
baculovirus (hCD154).  IgM-secreting cells in replicate cultures are enumerated ± S.E. as 
described in Materials and Methods.  Results are representative of two similar 
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experiments.  B.  Cells were stimulated with 2 µg/ml agonistic α-mCD40 mAb, α-
hCD40 mAb, or isotype control mAbs for 72 hours as described in Methods.  Data 
represent fold increase in Pfc: mean Pfc of replicate cultures stimulated through CD40 
divided by mean Pfc of replicate cultures of cells stimulated with isotype control mAbs, 
and are the mean values of three separate experiments.  C.  CH12.LX cells stably 
expressing hCD40WT, hCD40-P227A (P227A.1), or a chimeric molecule consisting of 
the extracellular and transmembrane domains of hCD40 and the intracellular domain of 
LMP-1 (hCD40-LMP1) were stimulated as in 2B.  Data represent mean fold increase in 
Pfc over cells stimulated with isotype control antibodies, as in 2B, and are representative 
of 3 similar experiments.  D.  Cells were stimulated as indicated with 2 µg/ml agonistic 
α-mCD40 or α-hCD40 mAb ± 0.1% SRBC (Ag).  IgM production was measured as in 
3A, and is representative of two similar experiments.   Similar results were observed with 
a second subclone expressing hCD40-P227A.  Asterisk (*) denotes statistical difference 
(p<0.05) between hCD40WT and hCD40-P227A by two-tailed Student’s t-test. 
Figure 3:  IL-6 secretion stimulated by hCD40-P227A versus Wt hCD40. 
A.  CH12.hCD40WT (hCD40WT) or CH12.P227A (P227A.1, P227A.2, P227A.3) cells 
were stimulated as indicated with Hi5 cells (1:5 ratio with B cells) ± 10 µg/ml α-µ chain 
F(ab)’2 Ig for 48 hours and IL-6 ELISA was performed.  Two separate subclones of 
CH12.LX expressing hCD40WT were tested with similar results (not shown).  Data 
represent mean ± S.D. of triplicate cultures.  A representative experiment of five 
independent experiments with similar results is shown. Hi5-WTBV; Hi5 infected with Wt 
baculovirus.  B.  Cells were stimulated as in 3A for the indicated times and IL-6 ELISA 
was performed.  IL-6 was undetectable in supernatants from cells stimulated with media 
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(BCM) or with uninfected Hi5 cells.  A representative of three independent experiments 
with similar results is shown.  C. Cells were stimulated with 10 µg/ml agonistic α-
mCD40, α-hCD40, or isotype control mAbs ± 10 µg/ml α-µ chain F(ab)’2 Ab (α-BCR) 
or media (BCM) for 48 hours.  IL-6 ELISA was performed as described in Methods.  
Data represent mean ± S.D. of three independent experiments.  Two separate subclones 
of CH12.LX expressing hCD40WT were tested with similar results (not shown).  D.  
Cells were stimulated for 20 hours as indicated with Hi5 cells (1:5 ratio with B cells) ± 
25nM CpG 2084 or control CpG 2087 oligonucleotides.  Culture supernatants were 
analyzed by ELISA.  Data are representative of three independent experiments with 
similar results, and a second hCD40WT subclone was tested with similar results (not 
shown). Asterisk (*) denotes statistical difference (p<0.05) between hCD40WT and 
hCD40-P227A; ** denotes p<0.001 by two-tailed Student’s t-test.   
Figure 4: IL-6 secretion induced by mCD40-hP227A vs. mCD40-hCD40 in the 
human B cell line, T5-1.  T5-1.mCD40-hCD40 (MH40WT-n24.7, MHWT-n24.12) and 
T5-1.mCD40-hP227A (MHP227A-n22.7, MHP227A-n22.12) were stimulated with Hi5-
mCD154 + R848 for 48h and supernatants analyzed by ELISA for human IL-6.  Data are 
presented as mean ± S.D. of background-corrected IL-6 in replicate cultures from three 
separate experiments. Asterisk (*) denotes statistical difference (p<0.05) between 
MH40WT and MHP227A by two-tailed Student’s t-test. 
Figure 5:  TNF-α secretion induced by hCD40-P227A versus Wt hCD40.   
M12.hCD40WT (hCD40WT.1, hCD40WT.2) and M12.P227A (P227A.1, P227A.2) cells 
were stimulated for the indicated times and TNF-α ELISA was performed as described in 
Materials and Methods.  Data are presented as mean ± S.D. of background-corrected 
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TNF-α in replicate cultures from three separate experiments:  (mean TNF-α induced by 
Hi5-hCD154) – (mean TNF-α induced by MDM2 control virus-infected Hi5).  Asterisk 
(*) denotes statistical difference (p<0.05) between hCD40WT and hCD40-P227A by 
two-tailed Student’s t-test. 
Figure 6:  Activation of JNK, NF-κB, and c-Jun phosphorylation by hCD40-P227A 
versus Wt hCD40 signaling.   
A.  CH12.hCD40WT (hCD40WT.2) and CH12.P227A (P227A.1, P227A.2) cells were 
stimulated for the indicated times with medium (BCM), uninfected Hi5 (Hi5) or Hi5-
hCD154.  Total cell lysates were resolved by SDS-PAGE and immunoblotted for 
phosphorylated JNK, followed by total JNK as a loading control.  Data are representative 
of 3 independent experiments with multiple clones tested.  Results for P227A.2 are not 
included in the graph because its lower background produces a different scale.  B.  
CH12.hCD40WT (hCD40WT.1, hCD40WT.2) and CH12.P227A (P227A.1, P227A.2) 
cells were stimulated for the indicated times with media (BCM), uninfected Hi5 (Hi5) or 
Hi5-hCD154.  Total cell lysates were analyzed via SDS-PAGE and immunoblotted for 
phosphorylated c-Jun (Ser63), followed by actin as a loading control.  Results were 
quantified as described in Methods and are representative of 4 independent experiments.  
C.  M12.hCD40WT (hCD40WT.1, hCD40WT.2) and M12.P227A cells (P227A.1, 
P227A.2) were stimulated and total cell lysates prepared.  Samples were immunoblotted 
for phosphorylated c-Jun (Ser73) followed by actin as a loading control.  Results are 
representative of 5 experiments. 
Figure 7: TRAF binding and degradation upon signaling via hCD40-P227A and Wt 
hCD40.  A.  M12.hCD40WT or M12.hCD40-P227A (P227A.1, P227A.2) cells were 
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stimulated for 30 minutes with 1 Hi5: 5 B cells and cell lysates prepared.  The Brij 
insoluble fraction (I) represents the lipid raft fraction, whereas the Brij soluble fraction 
(S) represents the non-raft portion of the cell lysates.  hCD40 was immunoprecipitated as 
described
27 and subjected to SDS-PAGE and Western analysis for TRAF6, followed by 
TRAF1 (not shown), TRAF2, TRAF3, and hCD40.  Data are representative of three 
independent experiments.  A second hCD40WT clone was tested with similar results (not 
shown).  B.  CH12.hCD40WT (hCD40WT.1, hCD40WT.2) and CH12.P227A (P227A.1, 
P227A.2) were stimulated for the indicated times and cell lysates prepared. Membranes 
were immunoblotted for TRAF2, then stripped and reprobed for TRAF3 followed by 
GAPDH as a loading control.  Data are representative of > 3 experiments. 
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